1. Home
  2. JQC vs ABUS Comparison

JQC vs ABUS Comparison

Compare JQC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

HOLD

Current Price

$4.80

Market Cap

753.9M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.06

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JQC
ABUS
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.9M
929.6M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
JQC
ABUS
Price
$4.80
$4.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
747.3K
2.1M
Earning Date
01-01-0001
05-14-2026
Dividend Yield
11.13%
N/A
EPS Growth
N/A
55.26
EPS
N/A
N/A
Revenue
N/A
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$239.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
128.21
52 Week Low
$4.62
$3.04
52 Week High
$5.58
$5.10

Technical Indicators

Market Signals
Indicator
JQC
ABUS
Relative Strength Index (RSI) 47.26 39.99
Support Level $4.69 $3.41
Resistance Level $4.89 $4.71
Average True Range (ATR) 0.05 0.20
MACD -0.00 -0.04
Stochastic Oscillator 23.08 9.46

Price Performance

Historical Comparison
JQC
ABUS

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: